Prevalence of Ocular Surface Complaints in Patients With Glaucoma Using Topical Intraocular Pressure-Lowering Medications

被引:263
|
作者
Fechtner, Robert D. [2 ]
Godfrey, David G. [3 ]
Budenz, Donald [4 ]
Stewart, Jeanette A. [1 ]
Stewart, William C. [1 ]
Jasek, Mark C. [5 ]
机构
[1] PRN Pharmaceut Res Network LLC, Dallas, TX 75240 USA
[2] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Ophthalmol, Newark, NJ 07103 USA
[3] Glaucoma Associates Texas, Dallas, TX USA
[4] Univ Miami, Bascom Palmer Eye Inst, Miami, FL USA
[5] Alcon Labs Inc, Ft Worth, TX 76101 USA
关键词
glaucoma; therapy; ocular surface disease; OSDI; prevalence; DRY EYE SYNDROME; OPHTHALMIC EMULSION; DISEASE; EFFICACY; MODERATE; SAFETY;
D O I
10.1097/ICO.0b013e3181c325b2
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To determine the prevalence of ocular surface disease (OSD) in patients with glaucoma using topical intraocular pressure (IOP) lowering therapy. Methods: This prospective observational study enrolled patients with primary open-angle glaucoma or ocular hypertension who were on a topical IOP-lowering medication regimen. Enrolled patients completed the ocular surface disease index (OSDI) and SDI scores (0-100, with 0 representing no symptoms) were calculated for each patient. Medical history, demographics, and concomitant medication information were also collected. Results: Overall, 630 patients from 10 sites participated. Of these, 305 patients (48.4%) had an OSDI score indicating either mild (n = 134, 21.3%), moderate (n = 84, 13.3%), or severe (n = 87, 13.8%) OSD symptoms. OSDI scores were significantly different between patients with and without a prior diagnosis of dry eye syndrome (25.2 +/- 15.4 vs 15.4 +/- 15.8, respectively; P = 0.0036) and between patients who did and did not use artificial tears at the time of study participation (23.0 +/- 15.6 vs 15.3 +/- 15.8, respectively; P = 0.0046). Mean OSDI scores varied significantly with the number of topical IOP-lowering medications used, with higher (more severe) OSDI scores in patients using multiple IOP-lowering medications. Specifically, patients on a single medication had a mean OSDI score of 12.9 +/- 13.1, which was significantly lower than those of patients on 2 (16.7 +/- 17.0; P = 0.007) or 3 medications (19.4 +/- 18.1; P = 0.0001). Conclusions: OSD is prevalent among medically treated patients with glaucoma. The severity of OSD symptoms is positively correlated to the number of IOP-lowering medications used.
引用
收藏
页码:618 / 621
页数:4
相关论文
共 50 条
  • [31] Prevalence of ocular surface disease in glaucoma patients
    Leung, Eamon W.
    Medeiros, Felipe A.
    Weinreb, Robert N.
    JOURNAL OF GLAUCOMA, 2008, 17 (05) : 350 - 355
  • [32] Intraocular pressure-lowering effects and safety of brimonidine/brinzolamide fixed combination after switching from other medications
    Inoue, Kenji
    Kunimatsu-Sanuki, Shiho
    Ishida, Kyoko
    Tomita, Goji
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2022, 66 (05) : 440 - 446
  • [33] Intraocular pressure-lowering efficacy and ocular safety of Rho-kinase inhibitor in glaucoma: a meta-analysis and systematic review of prospective randomized trials
    Jo-Hsuan Wu
    Sheng-Nan Chang
    Takashi Nishida
    Bo-I Kuo
    Jou-Wei Lin
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260 : 937 - 948
  • [34] Efficacy of Topical 0.05% Cyclosporine A for Ocular Surface Disease Related to Topical Anti-Glaucoma Medications
    Kim, Jae-Gon
    An, Jae-Hong
    Cho, Soon Young
    Lee, Chong Eun
    Shim, Kyu Young
    Jun, Jong Hwa
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2023, 39 (06) : 389 - 397
  • [35] First and second transscleral cyclophotocoagulation treatments provide similar intraocular pressure-lowering efficacy in patients with refractory glaucoma
    Enrico Bernardi
    Marc Töteberg-Harms
    International Ophthalmology, 2022, 42 : 2363 - 2369
  • [36] Intraocular Pressure-Lowering Potential of Subthreshold Selective Laser Trabeculoplasty in Patients with Primary Open-Angle Glaucoma
    Zhang, Hong Yang
    Qin, Yong Jie
    Yang, Yang Fan
    Xu, Jian Gang
    Yu, Min Bin
    JOURNAL OF OPHTHALMOLOGY, 2016, 2016
  • [37] Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma
    Takashi Komizo
    Takashi Ono
    Akiko Yagi
    Kazunori Miyata
    Makoto Aihara
    Japanese Journal of Ophthalmology, 2019, 63 : 40 - 45
  • [38] Effectiveness of netarsudil 0.02% in lowering intraocular pressure in patients with secondary glaucoma
    Oydanich, Marko
    Roll, Elizabeth H.
    Uppuluri, Siri
    Khouri, Albert S.
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2024, 59 (04): : 247 - 252
  • [39] The Effect of Intraocular Pressure-lowering Eye Drops on Myopic Retinoschisis Patients
    Lee, Jung Hwa
    Jang, Kyu Hwan
    Lee, Suchan
    Kong, Mingui
    Sohn, Joon Hong
    JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, 2020, 61 (04): : 341 - 346
  • [40] Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5 % timolol in normal-tension glaucoma patients
    Kim, Joon Mo
    Kim, Tae-Woo
    Kim, Chan Yun
    Kim, Hwang Ki
    Park, Ki Ho
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2016, 60 (01) : 20 - 26